CLINICAL TRIALS FOR GRIN2BMedication Icon

Participating in clinical trials is an important way to help accelerate therapeutic development. There is currently one GRIN2B study open. Find more information about the study and future studies below.

 

GRIN THERAPEUTICS: RAD-GRIN-101

HONEYCOMB STUDY

GRIN Therapeutics is pleased to share information about a clinical trial opportunity for patients with GRIN2B-Related Neurodevelopmental Disorder in patients aged 6 months to 12 years. 

Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. Subjects’ participation in the study is expected to last up to six months.

The study is open-label, so all participants will be treated with radiprodil. After the end of this study, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label extension period.

As of August 2023, the trial is currently only enrolling patients in Spain, Netherlands, Germany and Italy. Additional countries will be added as they are approved. Please check back for updates.

Visit the RAD-GRIN-101 Study info at clinicaltrials.gov for the most up-to-date information on sites actively enrolling patients in the study. 

Take the web screener to see if your child qualifies for the study.

Read the press release from GRIN Therapeutics.

Disclaimer – GRIN2B Foundation is passing this information along to you for information purposes; please check with your doctor first to see if your child should participate.